Cantor Fitzgerald analyst Eliana Merle reiterated an Overweight rating and $15.00 price target on CymaBay Therapeutic (NASDAQ: CBAY) after the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Momentum Movers Trader Talk

Raymond James Upgrades CymaBay Therapeutic (CBAY) to Strong Buy as FDA Lifts Clinical Holds on SeladelparJuly 23, 2020 9:41 AM Pre-Open Movers 07/23: (CBAY) (NTGR) (HZO) Higher; (LLNW) (ALGN) (MSFT) Lower (more...)July 23, 2020 9:31 AM CymaBay Therapeutics (CBAY) Announces FDA Lifts All Clinical Holds on SeladelparJuly 23, 2020 8:04 AM FDA Lifts All Clinical Holds on SeladelparJuly 23, 2020 8:00 AM